1 / 1

Clinical Study Overview: Intervention Allocation and Follow-Up Analysis in Cancer Treatment

This clinical study focuses on the allocation of patients to two groups: placebo with docetaxel and aflibercept with docetaxel. Among participants, 88% were randomized, with 44 receiving the allocated intervention for placebo, and all 43 for aflibercept. Discontinuation reasons included adverse events (9%), disease progression (20%), and patient/investigator decisions. Follow-up analysis was conducted in cycles 1 and 3, noting exclusions due to ECG data loss. These insights could guide future cancer treatment protocols and patient management strategies.

tave
Télécharger la présentation

Clinical Study Overview: Intervention Allocation and Follow-Up Analysis in Cancer Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Randomized (n= 88) Allocated to placebo and docetaxel (n= 45) ¨Received allocated intervention (n= 44) ¨Did not receive allocated intervention having failed exclusion criteria (n= 1) Allocated to aflibercept and docetaxel (n= 43) ¨Received allocated intervention (n= 43) ¨Did not receive allocated intervention (give reasons) (n= 0) Allocation Lost to follow-up (n= 0) Discontinued intervention (n= 35) ¨Adverse event (n= 9) ¨Disease progression (n= 20) ¨Patient decision (n= 2) ¨Investigator decision (n= 3) ¨Withdrew consent (n= 1) • Lost to follow-up (n= 0) • Discontinued intervention (n= 38) • ¨Adverse event (n= 7) • ¨Disease progression (n= 21) • ¨Patient decision (n= 4) • ¨Investigator decision (n= 3) • ¨Withdrew consent (n= 2) • ¨ Other (n= 1) Follow-Up Analysed in Cycle 1 (n= 43)¨Excluded from analysis due to ECG data loss (n= 1) Analysed in Cycle 3 (n= 31) ¨Excluded from analysis having discontinued from study (n= 12) Analysed in Cycle 1 (n= 41)¨Excluded from analysis due to ECG data loss (n= 2) Analysed in Cycle 3 (n= 28) ¨Excluded from analysis having discontinued from study (n= 12) ¨Excluded from analysis due to ECG data loss (n= 1) Analysis Supplemental Figure 1

More Related